Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$62.34 - $142.00
Previous CloseN/A
Volume488.69K
Average Volume (3M)4.35M
Market Cap
$28.84B
Enterprise Value$27.60B
Total Cash (Recent Filing)$606.10M
Total Debt (Recent Filing)$2.53B
Price to Earnings (P/E)51.8
Beta0.97
Next Earnings
Apr 24, 2025EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.42
Shares Outstanding390,772,000
10 Day Avg. Volume4,748,259
30 Day Avg. Volume4,354,486
Financial Highlights & Ratios
PEG Ratio12.21
Price to Book (P/B)N/A
Price to Sales (P/S)7.15
Price to Cash Flow (P/CF)23.90
P/FCF Ratio23.80
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.19
Enterprise Value/Ebitda30.19
Forecast
1Y Price Target
$103.40Price Target Upside37.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Market AdoptionThe updates from the ATTD conference are seen as incremental positives supporting accelerating adoption in Type 1 and Type 2 diabetes.
Product InnovationThe G7 15-day sensor's MARD data underscores a strong value proposition, expected to be well-received by investors.
Bears Say
Regulatory ChallengesDexcom announced it had received a warning letter from the FDA following the agency’s inspection of its Mesa and San Diego facilities, which added near-term pressure on the stock.
---
Ownership Overview
0.46% Insiders
27.55% Mutual Funds
26.36% Other Institutional Investors
15.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $62.34 and its highest was $142.00 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $28.84B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Apr 24, 2025 which is in 30 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Feb 13, 2025. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.479 by -$0.029.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.33.
How many shares outstanding does Dexcom have?
Dexcom has 390,772,000 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.45 in its last earnings report, missing expectations of $0.479. Following the earnings report the stock price went up 5.922%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
---
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$103.40 (37.28% Upside)
$103.40 (37.28% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 72%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $432.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.68%
12-Months-Change
Fundamentals
Return on Equity
27.63%
Trailing 12-Months
Asset Growth
3.51%
Trailing 12-Months
Company Description
Dexcom
Dexcom, Inc. is a leading medical device company that specializes in developing, manufacturing, and distributing continuous glucose monitoring (CGM) systems for diabetes management. Operating primarily within the healthcare and technology sectors, Dexcom's core products are designed to provide real-time glucose monitoring for patients, enabling better diabetes management and improving patient outcomes. The company is headquartered in San Diego, California, and has a global presence, serving patients and healthcare providers worldwide.
---
DXCM Company Deck
---
DXCM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for DexCom, with strong revenue growth, significant customer base expansion, and successful international market performance. However, challenges such as gross margin decline and operating income reduction were noted, indicating areas for improvement.Read More>---
DXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$103.40
▲(37.28% Upside)
Technical Analysis
Abbott Laboratories
―
Insulet
―
Medtronic
―
Tandem Diabetes Care
―
Senseonics Holdings
―
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
34/46 ratings generated profit
1 Year Average Return
+38.02%
assigned a buy rating 5 months ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 73.91% of your transactions generating a profit, with an average return of +38.02% per trade.
---